Combined capabilities provide scientists with access to new and existing immortalized cell lines for use in broad research applications and clinical markets.
Haplogen, a biotechnology company developing antiviral therapies, and CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, today announced that they are making available their large collection of human cell lines that are deficient for single genes, which they have been building over the past three years as part of a public-private partnership.
Cross-contamination of human cell lines with other cell lines and/or misidentification of cell cultures is reported to be 18-36 percent. Find out one way to prevent contamination in your lab.
We’ve updated our Privacy Policy to make it clearer how we use your personal data.
Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.